University of Michigan

Chimerix, Inc.

The University of North Carolina at Chapel Hill

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Andrew Louis McIver

Leroy B Townsend

John Charles Drach

Roy Wendell Ware

Ernest Randall Lanier, Jr

Ramamurty V S Changalvala

Dean Wallace Selleseth

John Henry Bougher, Iii

Bradley David Robertson

Phiroze Behram Sethna

Xiaodong Wang

Aaron Leigh Downey

Li Liu

Weihe Zhang

Anton Simeonov

Ajit Jadhav

Min Shen

Matthew Brian Boxer

Dmitri Kireev

Kyle Ryan Brimacombe

Jason Matthew Rohde

Mindy Irene Emily Davis

Rajan Pragani

Surendra Karavadhi

Jing Liu

Stephen Frye

Matthew E Hall

Daniel Jason Urban

Natalia Martinez

Dehui Zhang

Yuhong Fang

Wei Zhao

Matthew Hall

John Henry Iii Bougher

The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rand A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.

Pyrrolopyrimidine nucleosides and analogs thereof

The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rand A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II. 

A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; Rand Rare each independently a halogen, CN, CF, CHF, CHF, a C-C10alkyl group, a C1-Calkoxy group, a di(C-Calkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X, X, Rand Rare disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed. 

Mutant IDH1 inhibitors useful for treating cancer

Compounds of Formula I or II: are described, along with pharmaceutical compositions containing the same and methods of using such compounds for the treatment of cancer.

Pyrimidine compounds for the treatment of cancer

Described are compounds of Formula I or Formula II: wherein: ring A is a 5- or 6-membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described. 

Growing community of inventors

Durham, NC, United States of America

Andrew Louis McIver